CCIA
YMAB

Campbell & Co Investment Adviser’s Y-mAbs Therapeutics YMAB Stock Holding History

Campbell & Co Investment Adviser’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,850
Closed -$140K – 1391
2024
Q4 		$140K Sell
17,850
-38,740
-68% -$472K 0.01% 1001
2024
Q3 		$744K Sell
56,590
-5,456
-9% -$69.2K 0.06% 551
2024
Q2 		$750K Sell
62,046
-14,394
-19% -$194K 0.06% 489
2024
Q1 		$1.24M Sell
76,440
-5,951
-7% -$80.2K 0.11% 308
2023
Q4 		$562K Buy
+82,391
New +$477K 0.05% 653

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Campbell & Co Investment Adviser's YMAB Position: Q1 2025 in Review

Campbell & Co Investment Adviser sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 17,850 shares — an estimated $140K sold.

Campbell & Co Investment Adviser first reported a position in YMAB in Q4 2023 and held it in 5 quarters. The position peaked at $1.24M in Q1 2024. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Campbell & Co Investment Adviser reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 17,850 Y-mAbs Therapeutics shares in Q1 2025, an estimated $140K.
  • Campbell & Co Investment Adviser first reported a position in Y-mAbs Therapeutics in Q4 2023 and held it in 5 quarters.
  • Campbell & Co Investment Adviser's Y-mAbs Therapeutics position peaked at $1.24M in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2025, filed 14 May 2025.